Younis, Tallal and Skedgel, Chris ORCID: https://orcid.org/0000-0003-4989-8846
(2011)
Adjuvant trastuzumab for breast cancer:Uncertainties in clinical and economic evidence following early stopping of the HERA trial.
PharmacoEconomics, 29 (5).
pp. 361-365.
ISSN 1170-7690
Item Type: | Article |
---|---|
Uncontrolled Keywords: | antibodies, monoclonal, humanized,antineoplastic agents,breast neoplasms,chemotherapy,cost-benefit analysis,disease-free survival,early termination of clinical trials,female,humans,randomized controlled trials as topic,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being |
Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
Depositing User: | Pure Connector |
Date Deposited: | 03 Feb 2015 13:14 |
Last Modified: | 21 Oct 2022 00:29 |
URI: | https://ueaeprints.uea.ac.uk/id/eprint/51930 |
DOI: | 10.2165/11588350-000000000-00000 |
Actions (login required)
![]() |
View Item |